Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-14
2005-06-14
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004300, C514S04400A, C435S004000, C435S006120, C435S007100
Reexamination Certificate
active
06906026
ABSTRACT:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
REFERENCES:
patent: 5571714 (1996-11-01), Dasch et al.
patent: 5824655 (1998-10-01), Border
patent: 6316258 (2001-11-01), Noble et al.
patent: WO91/04748 (1991-04-01), None
patent: WO93/09800 (1993-05-01), None
patent: WO93/10808 (1993-06-01), None
patent: WO96/25178 (1996-08-01), None
patent: WO97/39028 (1997-10-01), None
patent: WO99/34823 (1999-07-01), None
Moll et al., Kidney International, vol. 48: 1459-1468, 1995.
Abboud, Hanna E., “Platelet-derived growth factor and mesangial cells,”Kidney International, 41:581-3, 1992 (Exhibit 8).
Anderson, Sharon et al., “Control of Glomerular Hypertension Limits Glomerular Injury in Rats with Reduced Renal Mass,”The Journal of Clinical Investigation, 76:612-9, 1985 (Exhibit 9).
Antonipillai, I. et al., “Transforming growth factor-β is a renin secretagogue at picomolar concentrations,”American Journal of Physiology, 265:F537-41, 1993 (Exhibit 10).
Arai, N. et al., “Complete Nucleotide Sequence of the Chromosomal Gene for Human IL-4 and Its Expression,”Journal of Immunology, 142:274-82, 1989 (Exhibit 11).
Arai, Makoto et al., “In Vivo Transfection of Genes for Renin and Angiotensinogen into the Glomerular Cells Induced Phenotypic Change of the Mesangial Cells and Glomerular Sclerosis,”Biochemical and Biophysical Research Communications, 206:525-32, 1995 (Exhibit 12).
Armelin, Hugo A., “Pituitary Extracts and Steroid Hormones in the Control of 3T3 Cell Growth (mouse fibroblasts/growth factor),”Proceedings of the National Academy of Sciences USA, 70:2702-6, 1973 (Exhibit 13).
Arnheim, Norman and Henry Erlich, “Polymerase Chain Reaction Strategy,”Annual Review of Biochemistry, 61:131-56, 1992 (Exhibit 14).
Badasso, M. et al., “Crystallization and Preliminary X-ray Analysis of Complexes of Peptide Inhibitors with Human Recombinant and Mouse Submandibular Renins,”Journal of Molecular Biology, 223:447-53, 1992 (Exhibit 15).
Bagchus, W. M. et al., “Glomerulonephritis Induced by Monoclonal Anti-Thy 1.1 Antibodies,”Laboratory Investigation, 55:680-7, 1986 (Exhibit 16).
Chakraborty, Asit K. et al., “Synthetic retrotransposon vectors for gene therapy,”FASEB Journal, 7:971-7, 1993 (Exhibit 35).
Chansel, Dominique et al., “Identification and regulation of renin in human cultured mesangial cells,”American Journal of Physiology, 252:F32-8, 1987 (Exhibit 36).
Ciccarone, Valentina C. et al., “Identification of Enhancer-like Elements in Human IFN-γ Genomic DNA,”Journal of Immunology, 144:725-30, 1990 (Exhibit 37).
Coffin, in Weiss et al. (Eds.), RNA Tumor Viruses, 2nd Ed., vol. 2, Cold Spring Laboratory, NY, pp. 17-73, 1985 (Exhibit 38).
Cole, S. P. C. et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,”Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. 77-96, 1985 (Exhibit 39).
Compagnon, B. et al., “Targeting of Poly(rl)-Poly(rC) by Fusogenic (F Protein) Immunoliposomes,”Experimental Cell Research, 200:333-8, 1992 (Exhibit 40).
Cook, R. Frank et al., “Retrotransposon Gene Engineering,”Biotechnology, 9:748-51, 1991 (Exhibit 41).
Cote, Richard J. et al., “Generation of human monoclonal antibodies reactive with cellular antigens,”Proceedings of the National Academy of Sciences USA, 80:2026-30, 1983 (Exhibit 42).
DePamphilis, M. L. et al., “Microinjecting DNA into Mouse Ova to Study DNA Replication and Gene Expression and to Produce Transgenic Animals,”BioTechniques, 6:662-80, 1988 (Exhibit 43).
Dhanaraj, V. et al., “X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins,”Nature, 357:466-72, 1992 (Exhibit 44).
Dostal, David E. et al., “An Improved Method for Absolute Quantification of mRNA Using Multiplex Polymerase Chain Reaction: Determination of Renin and Angiotensinogen mRNA Levels in Various Tissues,”Analytical Biochemistry, 223:239-50, 1994 (Exhibit 45).
Dzau, Victor J. and Jeffrey Kreisberg, “Cultured Glomerular Mesangial Cells Contain Renin: Influence of Calcium and Isoproterenol,”Journal of Cardiovascular Pharmacology, 8:S6-10, 1986 (Exhibit 46).
Eltayeb, B. O. et al., “Effects of captopril on serum levels of TGF-β in insulin-dependent diabetic patients,”Journal of the American Society of Nephrology, 8:AO524, 1997 (Exhibit 47).
Felgner, Philip L. et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proceedings of the National Academy of Sciences USA, 84:7413-7, 1987 (Exhibit 48).
Felgner, P. L. et al., “Cationic Liposome Mediated Transfection,”Proceedings of the Western Pharmacology Society, 32:115-21, 1989 (Exhibit 49).
Felgner, P. L. and G. Rhodes, “Gene therapeutics,”Nature, 349:351-2, 1991 (Exhibit 50).
Fischli, Walter et al., “Ro 42-5892 is a Potent Orally Active Renin Inhibitor in Primates,”Hypertension, 18:22-31, 1991 (Exhibit 51).
Flaumenhaft, Robert et al., “Activation of Latent Transforming Growth Factor β,”Advances in Pharmacology, 24:51-76, 1993 (Exhibit 52).
Fujita, Takashi et al., “Regulation of Human Interleukin-2 Gene: Functional DNA Sequences in the 5′ Flanking Region for the Gene Expression in Activated T Lymphocytes,”Cell, 46:401-7, 1986 (Exhibit 53).
Baricos, William H. et al., “ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade,”Kidney International, 47:1039-47, 1995 (Exhibit 17).
Baricos, William H. et al. “Transforming Growth Factor-β is a Potent Inhibitor of Extracellular Matrix Degradation by Cultured Human Mesangial Cells,”Journal of the American Society of Nephrology, 10:790-5, 1999 (Exhibit 18).
Beaucage, S. L. and M. H. Caruthers, “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,”Tetrahedron Letters, 22:1859-62, 1981 (Exhibit 19).
Bennett, C. Frank et al., “Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides,”Molecular Pharmacology, 41:1023-33, 1992 (Exhibit 20).
Bongartz, Jean-Pierre et al., “Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide,”Nucleic Acids Research, 22:4681-8, 1994 (Exhibit 21).
Border, Wayne A. and Nancy A. Noble, “Transforming Growth Factor β in Tissue Fibrosis,”New England Journal of Medicine, 331:1286-92, 1994 (Exhibit 22).
Border, Wayne A. and Nancy A. Noble, “TGF-β in kidney fibrosis: A target for gene therapy,”Kidney International, 51:1388-96, 1997 (Exhibit 23).
Border, Wayne A. and Nancy A. Noble, “TGF-β,”Scientific American Science&Medicine, 2:68-77, 1995 (Exhibit 24).
Border, Wayne A. and Nancy A. Noble, “Evidence that TGF-β should be a therapeutic target in diabetic nephropathy,”Kidney International, 54:1390-1, 1998 (Exhibit 25).
Border, Wayne A. and Nancy A. Noble, “Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis,”Hypertension, 31:181-8, 1998 (Exhibit 26).
Border, Wayne A. and Erkki Ruoslahti, “Transforming Growth Factor-β in Disease: The Dark Side of Tissue Repair,
Border Wayne A.
Noble Nancy A.
Mandel & Adriano
McGarry Sean
The University of Research Foundation
LandOfFree
Methods for treating conditions associated with the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating conditions associated with the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating conditions associated with the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3506766